TherapeuticsMD, Inc.
TXMD
$1.46
-$0.06-3.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 784.00K | 952.00K | 393.00K | 667.00K | 547.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 784.00K | 952.00K | 393.00K | 667.00K | 547.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 784.00K | 952.00K | 393.00K | 667.00K | 547.00K |
| SG&A Expenses | 984.00K | 1.18M | 1.08M | 879.00K | 1.31M |
| Depreciation & Amortization | 96.00K | 96.00K | 95.00K | 100.00K | 96.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.08M | 1.27M | 1.18M | 979.00K | 1.41M |
| Operating Income | -296.00K | -319.00K | -783.00K | -312.00K | -859.00K |
| Income Before Tax | 50.00K | 545.00K | -668.00K | 83.00K | -567.00K |
| Income Tax Expenses | -- | -- | -32.00K | -31.00K | -- |
| Earnings from Continuing Operations | 50.00K | 545.00K | -636.00K | 114.00K | -567.00K |
| Earnings from Discontinued Operations | 102.00K | 6.00K | -17.00K | 138.00K | -42.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 152.00K | 551.00K | -653.00K | 252.00K | -609.00K |
| EBIT | -296.00K | -319.00K | -783.00K | -312.00K | -859.00K |
| EBITDA | -200.00K | -223.00K | -688.00K | -212.00K | -763.00K |
| EPS Basic | 0.01 | 0.05 | -0.06 | 0.02 | -0.05 |
| Normalized Basic EPS | 0.00 | 0.03 | -0.03 | -0.06 | -0.03 |
| EPS Diluted | 0.01 | 0.05 | -0.06 | 0.02 | -0.05 |
| Normalized Diluted EPS | 0.00 | 0.03 | -0.03 | -0.06 | -0.03 |
| Average Basic Shares Outstanding | 11.57M | 11.57M | 11.55M | 11.53M | 11.53M |
| Average Diluted Shares Outstanding | 11.57M | 11.57M | 11.55M | 11.53M | 11.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |